@TiansterZhang@dukemedicine@DukeCancer You are a rockstar of GU Oncology at Duke. Will miss you loads. You will be a rockstar at UT Southwestern as well. Will follow you for many more advancements in future.
Excited to share our team science paper on race, ancestry, and abiraterone outcomes in men with mCRPC now out in Cancer! Led by @Daniel_J_George and our team at @DukeGUCancer@DukeCancer@ThePCCTC and amazing partners. @sartor_oliver https://t.co/I6Anunu8sZ
It’s official! Come August, I will be moving to the great city of #Baltimore to begin a PhD in US History at @JohnsHopkins, where I will be advised by the brilliant & exceptionally kind @angusburgin. Thank you to everyone who played a hand in this journey. I cannot wait! 🙏🏼🎉
CTC genotyping provides insights into primary and acquired enzalutamide and abiraterone resistance in men with mCRPC: https://t.co/mq4H5oXeB7 @DukeGUCancer@DukeCancer@WCM_MeyerCancer from our prospective PROPHECY trial
Excited to share that I'll be presenting a paper, inspired by my master's dissertation research at @LSEEcHist, next week at @CSELatASU's Winter Institute in the History of Economic Thought. Anyone is welcome to register for the event at https://t.co/VUmge6bCMC. @Societies_HET
New in prostate cancer: PCCTC study finds detection of AR-V7 in circulating tumor cells by 2 different blood-based assays is independently associated with shorter PFS and OS with abiraterone or enzalutamide
Wow, nearly 100 investigators, staff and sponsors on our calls this week. Great momentum leading into next year. Such an important resource we are building together. Thanks to everyone involved.
If exercise readies the immune system for a fight, what better way to prepare for what is likely the fight of a person’s life—cancer? @Bartlett_Lab & @MRHarrisonMD are investigating whether exercise boosts the effectiveness of immunotherapy treatments. https://t.co/yQvToLN5GN